Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Cancer drug efficacy is often linked to a patient's genetic makeup.
• Specific genetic alterations (e.g., EGFR, BRAF, HER2) influence treatment strategies.
• Tumor genomic profiling provides actionable insights for personalized medicine.

Purpose of the Study:

• To review the role of genetic testing in tailoring cancer drug administration.
• To highlight the impact of genomic alterations on treatment selection across various cancer types.
• To emphasize the growing importance of agnostic genomic testing in oncology.

Main Methods:

• Review of current literature on cancer genomics and targeted therapies.
• Analysis of genetic testing requirements for common cancers like lung, colorectal, and breast cancer.
• Discussion of multilocus assays and agnostic testing approaches.

Main Results:

• Genetic alterations such as EGFR, BRAF, HER2, ALK, MET, and KRAS mutations/amplifications necessitate specific drug choices.
• Tumor mutation burden and DNA repair deficiencies are key genomic characteristics.
• Genomically tailored treatments have significantly improved outcomes for many cancer patients.

Conclusions:

• Personalized cancer therapy guided by genetic testing is revolutionizing patient care.
• Comprehensive genomic profiling across all tumor types is increasingly adopted.
• Targeted treatments based on specific genomic events offer substantial benefits in cancer treatment.